Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GoodRx Holdings, Inc.GDRX · Entity 4838 | Chief Financial Officer | January 08, 2025 | January 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GoodRx Holdings, Inc.
Report date January 08, 2025 · Filed January 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 363,561 |
Ending reported balance
After 2025-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-01-08 · Exercise / conversion · Acquired 89,292 · Balance 392,596 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Row 2 · 2025-01-08 · Tax withholding · Disposed 29,035 · Balance 363,561 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 267,876 |
Reported balance
After 2025-01-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-08 · Exercise / conversion · Disposed 89,292 · Balance 267,876 F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2: The restricted stock unit award will vest as to 25% of the underlying shares on January 8, 2025 with the remaining 75% to vest in approximately equal quarterly installments thereafter for 12 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
F2: The restricted stock unit award will vest as to 25% of the underlying shares on January 8, 2025 with the remaining 75% to vest in approximately equal quarterly installments thereafter for 12 quarters.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2021 Filed Sep 1, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 100 | $37.71 | $3,771.00 |
DisclosureSEC source: 0000899243-21-034726 · doc4.xml · nonDerivative · entry 3 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of November 16, 2020. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 12,400 | $37.00 | $458,756.60 |
DisclosureSEC source: 0000899243-21-034726 · doc4.xml · nonDerivative · entry 2 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of November 16, 2020. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $6.84 | $85,500.00 |
DisclosureSEC source: 0000899243-21-034726 · doc4.xml · nonDerivative · entry 1 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 18:01 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000899243-21-030851 · doc4.xml · derivative · entry 4 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Class A Common Stock · 12,500 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on March 2, 2020. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 18:01 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 7,842 | $32.92 | $258,132.76 |
DisclosureSEC source: 0000899243-21-030851 · doc4.xml · nonDerivative · entry 3 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of November 16, 2020. F3 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.80 to $33.01. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 18:01 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 4,658 | $32.46 | $151,214.98 |
DisclosureSEC source: 0000899243-21-030851 · doc4.xml · nonDerivative · entry 2 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,842 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of November 16, 2020. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.80 to $32.79. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 18:01 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $6.84 | $85,500.00 |
DisclosureSEC source: 0000899243-21-030851 · doc4.xml · nonDerivative · entry 1 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 16:35 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000899243-21-026752 · doc4.xml · derivative · entry 3 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,500 Underlying: Class A Common Stock · 12,500 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on March 2, 2020. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 16:35 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 12,500 | $37.37 | $467,161.25 |
DisclosureSEC source: 0000899243-21-026752 · doc4.xml · nonDerivative · entry 2 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of November 16, 2020. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.02 to $37.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 16:35 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $6.84 | $85,500.00 |
DisclosureSEC source: 0000899243-21-026752 · doc4.xml · nonDerivative · entry 1 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 18:25 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000899243-21-021633 · doc4.xml · derivative · entry 5 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Class A Common Stock · 12,500 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on March 2, 2020. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 18:25 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 250 | $39.09 | $9,772.50 |
DisclosureSEC source: 0000899243-21-021633 · doc4.xml · nonDerivative · entry 4 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This price reported in Column 4 is a werighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $39.14. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 18:25 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 4,281 | $38.58 | $165,177.25 |
DisclosureSEC source: 0000899243-21-021633 · doc4.xml · nonDerivative · entry 3 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This price reported in Column 4 is a werighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $39.01. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 18:25 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 7,969 | $37.49 | $298,793.67 |
DisclosureSEC source: 0000899243-21-021633 · doc4.xml · nonDerivative · entry 2 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,531 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.03 to $38.02. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 18:25 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $6.84 | $85,500.00 |
DisclosureSEC source: 0000899243-21-021633 · doc4.xml · nonDerivative · entry 1 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000899243-21-017622 · doc4.xml · derivative · entry 4 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,500 Underlying: Class A Common Stock · 12,500 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on March 2, 2020. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 501 | $41.05 | $20,567.50 |
DisclosureSEC source: 0000899243-21-017622 · doc4.xml · nonDerivative · entry 3 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This price reported in Column 4 is a werighted average price. These shares were sold in multiple transactions at prices ranging from $41.02 to $41.11. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 11,999 | $40.22 | $482,584.18 |
DisclosureSEC source: 0000899243-21-017622 · doc4.xml · nonDerivative · entry 2 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.95 to $40.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 16:05 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 12,500 | $6.84 | $85,500.00 |
DisclosureSEC source: 0000899243-21-017622 · doc4.xml · nonDerivative · entry 1 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000899243-21-014167 · doc4.xml · derivative · entry 5 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Class A Common Stock · 150,000 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on March 2, 2020 Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 100 | $38.54 | $3,854.00 |
DisclosureSEC source: 0000899243-21-014167 · doc4.xml · nonDerivative · entry 4 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 47,469 | $37.72 | $1,790,682.58 |
DisclosureSEC source: 0000899243-21-014167 · doc4.xml · nonDerivative · entry 3 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan F3 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.49 to 36.465. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | SaleClass A Common Stock | 102,431 | $37.03 | $3,793,009.69 |
DisclosureSEC source: 0000899243-21-014167 · doc4.xml · nonDerivative · entry 2 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,569 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan F2 · price: This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $37.47. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 16:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass A Common Stock | 150,000 | $6.84 | $1,026,000.00 |
DisclosureSEC source: 0000899243-21-014167 · doc4.xml · nonDerivative · entry 1 Voermann Karsten · CIK 0001822140 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.